Colorectal cancer is among the most common human malignancies, and remains a leading cause of cancer-related morbidity and mortality. Patients with rectal cancer, despite surgery, still have a significant probability of relapse and cancer-related death. Adjuvant treatment is a rapidly evolving field of rectal cancer treatment. The standard approach is a combination of chemotherapy and radiation therapy (RT). The combined chemotherapy and RT for rectal cancer has been shown to increase the proportion of patients cured of their disease.
5-FU is also used as an adjuvant chemotherapeutic agent for rectal cancers.
1) It has also been reported that 5-FU suppository delivery combined with radiation causes less systemic toxicity and is more effective than intravenous administration. 7) A conventional rectal suppository such as a suppository formulated with a polyethylene glycol base, which may soften or melt slowly in the site of application due to its relatively high melting point, cannot be rapidly absorbed in the mucous membranes of the absorption site. 8, 9) Furthermore, conventional suppositories, which may reach to the end of the canal of the application site, because of its poor mucoadhesive properties, lose drugs at that level, and may also allow the carried drugs to undergo the first-pass effect. 10) To solve these problems associated with the use of conventional solid suppository, it would be desirable to develop a novel solid suppository, which was a solid phase at room temperature and instantly melted at physiological temperature, and had mucoadhesive properties to such level that it would attach to the site of application, i.e. the rectal mucous membranes.
11)
Recently, we have established the mixture composed of poloxamer 188 (P188) and propylene glycol (PG) for suppository having the suitable melting point (30-37°C) and mucoadhesive property. 12) Thus, the purpose of this study is to investigate whether the solid suppository with P188 and PG is a candidate of rectal dosage form for 5-FU in treating not only rectal cancers but skin cancers in mice.
MATERIALS AND METHODS

Materials
The murine CT-26 colon carcinoma cell line was purchased from Korean Cell Line Bank (Seoul, Korea). Fetal bovine serum (FBS) was purchased from GIBCO (Grand Island, NY, U.S.A.). 5-FU was provided by Dong-A Chemical (Seoul, South Korea). P188 which is a copolymer of poly(oxyethylene)-poly(oxypropylene)-poly(oxyethylene) with the ratio of POE/POP of 80/20 and the molecular weight of 8350 was obtained from BF Goodrich (Breesville, OH, U.S.A.), and PG was from DC Chemical Co., Ltd. (Seoul, South Korea). Propylene glycol was of USP grade. The semipermeable membrane tube (Spectra membrane tubing No. 1) was from Spectrum Medical Industries Inc. (Los Angeles, California, U.S.A.).
Preparation of P188 and PG-Based Suppository P188 and PG were mixed and heated up to 55°C. 5-FU was then slowly added to the solution with continuous agitation. The resulting solution was then placed into the suppository mould and cooled down to 25°C. The melting point of the suppository was determined using DSC (Model 200, Netzsch, U.S.A.) at the raising temperature 10 K/min, as previously described. to prevent leakage, and then, placed into the dissolution tester (DST-600, Fine Chemical, Korea). The dissolution test was performed at 36.5°C and 100 rpm with 400 ml phosphate buffer (pH 4.4) as a dissolution medium using the paddle method as previously described.
11)
Dissolution Test
11) At 0.25, 0.5, 0.75, 1, 1.5, 2 and 3.5 h, 1 ml aliquotes of the medium were sampled and filtered, equal volumes of fresh medium were replaced to maintain the sink condition. The filtrates were analyzed by UV/visible variable wavelength detector (Philips, Model PU8730) at 254 nm (Kim et al., 2002). 5-FU was analyzed with a UV-VIS wavelength detector at 265 nm (Philips, Model PU 8730, Germany).
Cell Culture CT-26 cells were grown at 37°C in a humidified incubator with 5% CO 2 /95% air in an Dulbecco's modified eagle medium supplemented with 10% FBS, 1 mM sodium pyruvate, 200 IU/ml penicillin and 200 mg/ml of streptomycin. Culture medium was replaced every other day. After attaining confluence the cells were subcultured following trypsinization with 0.25% trypsin-EDTA solution.
Establishment of Tumor Models in Mice For rectal cancer model, ten BALB/C mice weighing 20-22 g supplied by Orient Co., Ltd. (Seoul, Korea) were used for each group in the experiment. The mice were anesthetized with ethyl ether and put on a supine position. Under an operative microscope, a 30-gauge needle was inserted into the submucosa of the posterior wall of the rectum just at the anal verge, then the needle was pierced within the submucosa up to the level about 7-8 mm above the anal verge. The needle can be seen beneath the mucosa under a microscope. CT-26 cells were injected slowly into the submucosa of the rectum as 1ϫ10 6 cells in 10 ml PBS, followed by slow withdrawal of the needle.
For the generation of subcutaneous tumors in mice, BALB/C male mice were inoculated with 1ϫ10 6 CT-26 cells in 100 ml phosphate buffer solution (PBS) into the subcutaneous tissue of the right flank. The tumor volume, first measured two weeks later and twice a week thereafter, was calculated using the formula Vϭ1/2 (d1ϫd2ϫd3), where d1, d2, and d3 are diameters measured by calipers in different directions. 13) Animal experiments were followed the ethical standards formulated in the institutional guidelines issued by the Korea National Institute of Health for the care and use of laboratory animals.
Treatment of Drugs For the mice having rectal tumors, 5-FU (120 mg/kg) was given once via oral or rectal route 7 d after the tumor injection. The dose of 5-FU was selected based on the previous other studies. 6, 7) In the case of subcutaneous tumors, mice were first administered with 5-FU either orally or via rectal suppository when tumor volume reached about 200 mm 3 , and thereafter every 3rd day. Glutamic Oxaloacetic Transaminase/Glutamic Pyruvic Transaminase (GOT/GPT) Assay GOT/GPT levels were measured by using a Serum Transaminase assay kit (Asan Pharm, Seoul, Korea) which is based on the Reitman-Frankel method.
14) The mouse serum (50 ml) was added to a 250 ml of mixture containing L-aspartic acid and a-ketoglutaric acid for GOT determination or to a 250 ml of mixture containing DL-alanine and a-ketoglutaric acid for GPT determination. After the mixture was incubated at 37°C for 1 h, 250 ml of 2,4-dinitrophenylhydrazine was added. After the mixture was incubated at 25°C for 20 min, 2.5 ml of 0.4 N NaOH was added. After 10 min, the change of absorbance was measured at 505 nm with UV-VIS spectrophotometer (Shimadzu, UV-1601).
Measurement of Lipid Peroxidation Tissue homogenate (0.4 ml) was added to 0.1 M potassium phosphate buffer (0.4 ml). After incubation for 4 h at 37°C, the mixture was added to 0.2 ml of 8.1% sodium dodecyl sulfate, 1.5 ml of 20% acetic acid solution (pH 3.5), and 1.5 ml of 0.8% thiobarbituric acid. The mixture was heated at 95°C for 1 h, chilled to room temperature, and extracted with 1 ml of ddH 2 O and 2.5 ml of n-butanol · pyridine mixture (15 : 1, v/v). The upper organic layer containing malondialdehyde produced by lipid peroxidation was measured at 532 nm. Synthetic malondialdehyde was used as an external standard, and the level of lipid peroxides was expressed as nmol of malondialdehyde per mg protein.
15)
Data Analysis Data were expressed as meanϮstandard error of the mean (S.E.M.) and were analyzed using one way analysis of variance (ANOVA) and Student-Newman-Keul's test for individual comparisons. p values of less than 0.05 are considered statistically significant.
RESULTS AND DISCUSSION
The P188 and PG mixtures were easily prepared by mixing, heating and cooling P188 and PG in a ratio of 80/20% (w/w), 70/30% and 50/50%, respectively. PG and P188 itself showed the peak melting point of at around Ϫ10°C and 55°C, respectively, whereas increasing concentration of PG shifted the DSC curve towards a lower temperature with the melting point of about 45, 32, 10°C, respectively in the P188 and PG mixtures as shown in Fig. 1 . Furthermore, their DSC curves had no peaks of P188 and PG, indicating that the P188 and PG mixtures composed of P188 and PG may not be a heterogeneous, but a homogeneous phase. The P188 and PG mixture at a ratio of 7/3 was selected as a suppository base, since it was a solid form at room temperature and instantly melted near the physiological temperature.
To test whether the ratio of P188/PG affects the dissolution rates of 5-FU from the suppositories, we performed the dissolution studies on the two formulations composed of 5% 5-FU and 95% the mixture of P188 and PG with the ratio of either 7/3 or 8/2. The 5-FU release from the suppository containing P188/PG (7/3) was significantly higher than P188/PG (8/2) as depicted in Fig. 2 , indicating that PG increases the dissolution rates of the drug from the suppository, which has also been observed in the dissolution rate of other drugs from the solid suppository with P188 and PG. 12) Therefore, not only the melting point but the dissolution profile supported that as a base for 5-FU solid suppository, the ratio of 7/3 for the mixture of P188/PG is the proper one. The higher dissolution rate in the suppository with higher PG content may be due to the lower melting point which facilitates the drug release at the physiological temperature.
To examine the effectiveness of the 5-FU suppository over the oral administration on the rectal cancers, the mice received 120 mg/kg 5-FU via oral and the suppository 7 d after inoculation of CT26 cancer cells within the submucosa of rectum. The 5-FU administered either orally or in the form of the P188/PG-based suppository significantly reduced the volume of rectal cancer. However, the anticancer effect of 5-FU in the suppository form was more prominent, as shown in Fig. 3A . Moreover, in a separate experiment, the 5-FU suppository administration on the 7th day of cancer cell inoculation into the rectum prolonged the survival of rectal cancer mice as shown in Fig. 3B .
In order to evaluate the effectiveness of the 5-FU suppository on the cancers other than rectal tissues, we also established and examined the anticancer effects of the 5-FU suppository on the skin tumor model. The volume of skin cancers treated with 5-FU in a three intermittent administration regimen either orally or via rectal suppository was decreased in a dose-dependent manner (Fig. 4) . However, rectal administration of 5-FU through the P188 and PG-based suppository was more effective than 5-FU oral treatment against CT26-derived skin cancers in mice. These results may be explained by the previous studies of other groups that 5-fluorouracil after oral administration undergoes first-pass metabolism by both the liver and intestinal mucosa. 15, 16) Next, we also investigated any difference in toxicity of oral or the suppository administration. The hepatic damage was assessed by measuring glutamic pyruvic transaminase (GPT) and glutamic oxaloacetic transaminase (GOT) activities in the serum as well as lipid peroxidation of liver tissue. The mice that received 40 or 120 mg/kg 5-FU orally or through rectal suppository showed no statistical difference in the toxicity grading of glutamic oxaloacetic transaminase/glutamic pyruvic transaminase (GOT/GPT) and lipid peroxidation (Fig. 5) . Previous other studies have also reported that 5-FU suppository administration is not inducing any side effect and is safer route than i.v. administration since i.v. but not suppository causes side effects of diarrhea, weight loss and myelosuppression in rats. 6) However, more studies are still required to manifest whether 5-FU rectal suppository based on P188 and PG does not induce any toxicity in gastrointestinal tract and hematopoiesis other than liver.
In conclusion, the present study clearly showed that treatment with 5-FU suppository composed of 70% P188 and 30% PG, which was a solid form at room temperature and instantly melted at physiological temperature, decreased the tumor size and increased the survival rate of rectal cancer mice. Moreover, our results further suggest that the 5-FU suppository may be an effective rectal dosage form for the treatment of not only rectal cancers but other cancer types.
